Nuravax Inc.

About Nuravax Inc.

Nuravax is a biotechnology company focused on preventing and curing central nervous system (CNS) disorders through immunotherapy. They aim to remove pathological proteins associated with Alzheimer's and Parkinson's diseases from the blood before they damage brain neurons, using their proprietary MultiTEP vaccine platform to design highly specific vaccine therapies.

Products & Services

MultiTEP Vaccine Platform:A unique platform designed to overcome common immunotherapy challenges, ensuring a robust immune response for vaccines targeting neurodegenerative diseases.

Alzheimer's Vaccine:A vaccine in development to combat Alzheimer's disease by targeting pathological proteins.

Specialties

Immunotherapy Vaccine Development Neurodegenerative Diseases Alzheimer's and Parkinson's Treatment MultiTEP Platform

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant (SBIR Fast-Track program) T: - FT: Grant (SBIR Fast-Track program)	A: 3000000 MR: - FA: $3 million FAN: 3000000	D: 2025-05-05 FD: 2025-05-05	1 investors

Grant (SBIR Fast-Track program) Latest

2025-05-05

$3.0M

1 investor (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

JAMES CALLAWAY

Ph.D., Head of Development

L

LON S. SCHNEIDER

Medical Director

M

MICHAEL AGADJANYAN

President

R

ROMAN KNIAZEV

Kauffman Fellow, CEO

D

DAVID H. CRIBBS

Ph.D., Scientific Director

A

ANAHIT GHOCHIKYAN

Chief Scientific Officer

View 5 more team members with Pro

Unlock Full Team Directory

Recent News

Nuravax Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised